A detailed history of Alpha Centric Advisors LLC transactions in Deciphera Pharmaceuticals, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 60,000 shares of DCPH stock, worth $0. This represents 0.65% of its overall portfolio holdings.

Number of Shares
60,000
Holding current value
$0
% of portfolio
0.65%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$13.58 - $17.36 $814,800 - $1.04 Million
60,000 New
60,000 $943,000
Q3 2023

Nov 13, 2023

BUY
$12.46 - $15.48 $679,070 - $843,660
54,500 Added 70.32%
132,000 $1.68 Million
Q2 2023

Aug 08, 2023

BUY
$13.28 - $15.96 $66,400 - $79,800
5,000 Added 6.9%
77,500 $1.09 Million
Q1 2023

May 12, 2023

BUY
$14.26 - $22.1 $1.03 Million - $1.6 Million
72,500 New
72,500 $1.12 Million
Q3 2020

Mar 11, 2022

SELL
$43.8 - $58.16 $8,760 - $11,632
-200 Closed
0 $0
Q2 2020

Mar 11, 2022

BUY
$37.05 - $65.03 $7,409 - $13,006
200 New
200 $12,000

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.